Bellevue Life Sciences Acquisition Corp.

General Information
Business:

We intend to focus our search on companies in the healthcare industry, specifically in the biotechnology sector. (Incorporated in Delaware)

Kuk Hyoun Hwang has been the CEO and a director of the company since March 2020. Mr. Hwang is the managing partner of Bellevue Capital Management (BCM), which he founded in August 2012. BCM is headquartered in Seattle, Washington, and is part of the local biotech hub ecosystem of the Greater Seattle area. BCM is also the South Korea advisor for Bellevue Asset Management (BAM), a subsidiary of Bellevue Group AG, a Swiss financial group holding company with global healthcare investing expertise. Bellevue Group AG is publicly listed on the Swiss Exchange (SIX) and oversees assets under management of approximately $11 billion, primarily invested in private and public equities across the global healthcare sector.

(Note: No pricing date has been set for Bellevue Life Sciences Acquisition Corp. Some on the Street, however, expect that this SPAC IPO may be priced sometime during the week of May 16, 2022.)

 

Industry: BLANK CHECKS
Employees: 0
Founded: 2020
Contact Information
Address 10900 NE 4th Street, Suite 2300 Bellevue, WA 98004
Phone Number (425) 635-7700
Web Address
View Prospectus: Bellevue Life Sciences Acquisition Corp.
Financial Information
Market Cap $78.9mil
Revenues $0 mil (last 12 months)
Net Income $0 mil (last 12 months)
IPO Profile
Symbol BLACU
Exchange NASDAQ
Shares (millions): 6.0
Price range $10.00 - $10.00
Est. $ Volume $60.0 mil
Manager / Joint Managers Chardan
CO-Managers -
Expected To Trade: 5/18/2022
Day: Day-to-Day
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change